Resumo Objetivo: Medir as tendências iniciais da função renal pela taxa de filtração glomerular (TFG) em pacientes com e sem comprometimento renal prévio após crioablação renal. Materiais e Métodos: Este é um estudo retrospectivo de 39 pacientes submetidos a crioablação percutânea guiada por tomografia computadorizada de massa renal. Os pacientes foram divididos em dois grupos: com comprometimento renal prévio (CRP+) e sem comprometimento renal prévio (CRP-). As tendências da TFG foram avaliadas nos tempos 0, 1, 6 e 12 meses com o estadiamento de doença renal crônica. Preditores da TFG em 1 e 6 meses foram modelados usando regressão linear. Resultados: Em ambos os grupos houve declínio da TFG média após 1 e 6 meses (p < 0,001 e p = 0,01, respectivamente). Apesar de o grupo CRP+ demonstrar média menor da TFG em cada um dos tempos (−26,1; p < 0,001), a tendência de forma geral não foi estatisticamente diferente do grupo CRP- (p = 0,89). Análise univariada mostrou correlação da TFG no tempo 0 (0,77 e 0,63; p < 0,001 e p = 0,03, respectivamente) e tamanho da ablação (−7,6 e −12,84; p = 0,03), com declínio em 1 e 6 meses. Porém, no modelo multivariado, apenas a TFG no tempo 0 foi preditiva da TFG em 1 mês (p < 0,001). Conclusão: A curva de tendência de declínio da TFG após crioablação foi similar entre os pacientes dos grupos CRP+ e CRP-, sem mudanças no estadiamento de função renal. A TFG no tempo 0 foi preditiva da TFG média no período de crioablação inicial.

Abstract Objective: To assess trends and predictors of the glomerular filtration rate (GFR) after renal mass cryoablation in patients with and without history of renal impairment. Materials and Methods: This was a retrospective study of 39 patients who underwent computed tomography-guided percutaneous cryoablation of a renal mass, divided into two groups: those with prior renal impairment (PRI+); and those without prior renal impairment (PRI−). The GFR trend and the chronic kidney disease stage were evaluated at baseline, as well as at 1, 6, and 12 months after cryoablation. Predictors of GFR at 1 and 6 months were modeled with linear regression. Results: In both groups, the mean GFR at 1 month and 6 months was significantly lower than at baseline (p < 0.001 and p = 0.01, respectively). Although the GFR was lower across all time points in the PRI+ group (−26.1; p < 0.001), the overall trend was not statistically different from that observed in the PRI− group (p = 0.89). Univariate analysis showed that the decline in GFR at 1 and 6 months correlated with the baseline GFR (0.77 and 0.63; p < 0.001 and p = 0.03, respectively) and with the size of the ablation zone (−7.6 and −12.84, respectively; p = 0.03 for both). However, in the multivariate model, baseline GFR was predictive only of GFR at 1 month (p < 0.001). Conclusion: The trend in GFR decline after cryoablation is similar for patients with and without a history of renal impairment. Baseline GFR predicts the mean GFR in the early post-cryoablation period.

BACKGROUND: Published criteria defining the accelerated phase in chronic myeloid leukemia are heterogeneous and little is known about predictors of poor outcome.METHODS: This is a retrospective study of 139 subjects in the accelerated phase of chronic myeloid leukemia treated with imatinib at a single center in Brazil. The objective was to identify risk factors for survival, major cytogenetic response and progression to blast phase in this population. The factors analyzed were: blasts 10-29%, basophils ≥ 20%, platelets > 1 × 106/µL or <1 × 105/µL and white blood cells > 1 × 105/µL in the peripheral blood, as well as clonal evolution, splenomegaly, hemoglobin < 10 g/dL, time between diagnosis of chronic myeloid leukemia and imatinib treatment, and hematologic toxicity.RESULTS: Risk factors for poor survival in multivariate analysis were Grades 3-4 hematologic toxicity (p-value = 0.001), blasts 10-29% (p-value = 0.023), and hemoglobin < 10 g/dL (p-value = 0.04). Risk factors for not achieving major cytogenetic response were blasts 10-29% (p-value = 0.007), hemoglobin < 10 g/dL (p-value = 0.001), and previous use of interferon (p-value = 0.032). Risk factors for progression to the blast phase were hemoglobin < 10 g/dL (p-value = 0.005), basophils ≥ 20% (p-value = 0.023), and time from diagnosis of chronic myeloid leukemia to imatinib treatment > 12 months (p-value = 0.030).CONCLUSION: These data indicate that patients with the above risk factors have a worse prognosis. This information can guide the therapy to be used.

Arte e Medicina frequentemente interagem das mais inusitadas maneiras. Muitas condições médicas podem ser encontradas em pinturas acadêmicas. O mesmo pode ocorrer com esculturas; no entanto, encontrar uma escultura em um espaço público exibindo sinais clínicos de parkinsonismo é um achado único. Relatou-se como “The Shaking Man”, que é uma estátua urbana localizada no Yerba Buena Gardens em São Francisco, EUA, pode ser uma representação contemporânea de parkinsonismo e foram realizadas comparações com outras obras de arte em diferentes mídias, as quais também demonstram parkinsonismo para o público leigo.

Art and Medicine often mingle in the most unexpected ways. One can often find in pictorial art the representation of many medical conditions. The same can happen with sculptures; however, the finding of an urban sculpture in a public space with features of parkinsonism is unique. We reported how “The Shaking Man”, an urban sculpture located in the Yerba Buena Gardens in San Francisco, USA, is a contemporary representation of parkinsonism and compared it with other art works in different media that also present such thing to laymen.